Last update: May 28, 2020, 12:00 p.m. CDT
We’re working to support care providers and patients during this challenging time. Below are resources and updates to help with ongoing patient care, along with changes to UnitedHealthcare programs and protocols as a result of the national public health emergency. Please check back often for the latest information.
Clinicians should not discontinue Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) medications for their patients with cardiovascular disease based solely on concerns related to COVID-19, as stated in evidence-based medicine protocols for members with cardiovascular disease.
Background and Cardiology Association Recommendations
Based on speculation that ACEI and ARB medications might worsen COVID-19 infectivity and outcomes, some public editorials have suggested that clinicians consider stopping the drugs during the COVID-19 national public health emergency period. Published case series, however, don’t provide evidence that supports such action at this time and there are no definitive clinical studies published on the issue at this time.
The European Society of Cardiology (ESC) Council on Hypertension has issued a statement that says, “The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy, because there is no clinical or scientific evidence to suggest that treatment with ACEI or ARBs should be discontinued because of the COVID-19 infection.”
The Heart Failure Society of America (HFSA), American College of Cardiology (ACC) and American Heart Association (AHA) said in a similar statement that they “recommend continuation of RAAS (Renin Angiotensin Aldosterone System) antagonists for those patients who are currently prescribed such agents for indications for which these agents are known to be beneficial, such as heart failure, hypertension or ischemic heart disease.”
If you need assistance with COVID-19 discharge planning, please email UnitedHealthcare at firstname.lastname@example.org. Your questions will be handled by a special team focused on COVID-19 discharge matters. During the national public health emergency period, we will generally respond to requests within two hours, from 8 a.m. to 8 p.m. Eastern Time. Team members are available to assist you seven days a week.
Things to keep in mind when you send your discharge planning questions
Please keep these tips in mind to help us coordinate our response to you and so we can respond to you efficiently and completely:
- Format your email subject line in the following way: [Facility/Institution Name; City, State]
- Include the following information in your email message:
- The name of your facility/institution
- The contact name of the person sending the email
- The contact information (phone and email) of the person sending the email.
- The name, date of birth and insurance policy number of the member you are inquiring about
- A brief description of the assistance you need from us
- As with all communications involving sensitive member information, please be sure to send your message to us in a secure manner.
Please note that we can also assist with discharge planning for all patients during this time, even if unrelated to COVID-19. You can email us at the address above if you have discharge planning questions unrelated to COVID-19.
The following information applies to commercial pharmacy benefit plans.
Previously, we announced planned changes to coverage for some medications. However, to allow additional time for you and your patients to discuss alternative therapies when appropriate, we’re extending the effective date of coverage changes for some medications from May 1, 2020, to July 1, 2020. This means the following exclusions will now take effect on July 1, 2020:
- Diabetes – Insulin: Basaglar® KwikPen®, Levemir®, Levemir® FlexTouch® and Tresiba®
- These insulins are currently excluded and will be added to coverage on July 1, 2020: Lantus®, Lantus® SoloSTAR®, Toujeo® Max SoloSTAR® and Toujeo® SoloSTAR®
- Diabetes – Non-Insulin: Janumet®, Janumet® XR and Januvia®
- Neuromuscular Disorders: Firdapse®
In addition, step therapy for Zomig® will be required effective July 1, 2020 instead of May 1, 2020.
Additionally, we won’t be excluding the following asthma/respiratory medications at this time. These will still be covered medications until further notice: Arnuity Ellipta®, Flovent® Diskus®, Flovent® HFA and Pulmicort Flexhaler®
Since multiple prescription drug lists and benefit variations may occur, you should refer to patient-specific information received through e-prescribing or our PreCheck MyScript® tool on Link. To learn more about PreCheck MyScript, go to UHCprovider.com/pcms.
Effective April 10, 2020, OptumRx home delivery pharmacy is placing its mandatory ePrescribing policy for controlled substances (EPCS) temporarily on hold until further notice. This policy went into effect on March 1, 2020 and required care providers to send e-prescriptions for controlled substances.
During the COVID-19 national public health emergency period, OptumRx home delivery pharmacy will fill any controlled substance prescription they receive, as long as the prescription meets federal and state regulatory requirements.
- Any care provider or member exemption will remain on file for a year from the date it was submitted.
- Please continue to email exemption requests to EPCSquestions@optum.com.
We’ll share updates as soon as OptumRx home delivery pharmacy determines when the EPCS requirement will resume.
Out of an abundance of caution, we paused HouseCalls and Optum At Home in-person visits with our members on March 20, 2020. This did not apply to services provided somewhere other than in private homes, such as telephone services and treating patients in skilled nursing facilities.
Effective May 22, we resumed in-person visits in some markets. We’re continuing virtual visits in other markets and we will continue to evaluate and resume in-person visits where possible.
UnitedHealthcare is closely monitoring the drug supply chain to determine if any coverage changes are necessary.
Early Prescription Refills
Through June 15, 2020, UnitedHealthcare members can fill existing prescriptions early (up to a 90-day refill) through direct pharmacy or mail order. To get an early refill, members can call the pharmacy number on their ID card or speak directly to a pharmacist.
The following information applies to all Medicare Advantage plans. As a result of the COVID-19 national public health emergency period, beginning March 1, 2020:
- We are not enforcing referral requirements on any plan for dates of service through June 15, 2020;
- We are covering services from out-of-network providers without a referral for dates of service through June 15, 2020; and
- For dates of service through June 15, referrals do not need to be entered into Link for plans that otherwise require that process.
Individual and Group Market Health Plans
The following information applies to all Individual and Group Market health plans.
- Consistent with existing policy, members do not need a referral for emergency care.
- All other standard referral requirements continue to apply.
- If a patient is unable to contact their primary care provider (PCP), they can contact Member Services for assistance with a referral. The number for Member Services can be found on their health plan ID card.
The following information applies to Medicaid plans.
- Consistent with existing policy, members do not need a referral for emergency care.
- The latest advisories, updates and process changes from state health plans can be found on the UnitedHealthcare Community Plan pages, where you’ll also find links to each state’s resources. Note that Florida, Maryland and Rhode Island have state requirements for referrals.
Any COVID-19-related changes that apply at a national level will be outlined on this site as new information becomes available.
We’re committed to keeping you up to date on COVID-19 – we’re monitoring your inquiries and working hard to answer your questions. Let us know how we’re doing.
We’ll be making daily updates to this site. Be sure to check back often for the latest information.
The benefits and processes described on this website apply pursuant to federal requirements and UnitedHealthcare national policy during the national emergency. Additional benefits or limitations may apply in some states and under some plans during this time.
We will adjudicate benefits in accordance with the member’s health plan.
Medicaid Providers: UnitedHealthcare will reimburse out-of-network providers for COVID-19 testing-related visits and COVID-19 related treatment or services according to the rates outlined in the Medicaid Fee Schedule.